From Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug:

Kathryn Wagner

Kathryn Wagner—

Kathryn Wagner, director of the Kennedy Krieger Institute’s center for genetic muscle disorders.

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Oct. 28 – Accelerating COVID-19 Drug Discovery: Qualified Assays for Proinflammatory Cytokines
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX

Sponsored · Webinar
Nov. 12 – High-Throughput Assessment of Compound-Induced Cardiotoxicity Using Human iPSC-Derived Cardiomyocytes
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX

Sponsored · Whitepaper
Bridging the Diversity Gap with Decentralized Trials
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!